$FGEN
FIBROGEN INC Stock $fgen

$fgen Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000156459022007632 Filed on February 28, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$16.54M	$235.3M	$65.00M
YoY Change	-74.55%	33.46%	712.5%
Cost Of Revenue	$3.125M	$12.87M	$2.600M
YoY Change	20.19%	45.12%	188.89%
Gross Profit	$13.42M	$222.4M	$62.40M
YoY Change	-78.5%	32.84%	778.87%
Gross Profit Margin	81.11%	94.53%	96.0%
Selling, General & Admin	$35.17M	$123.9M	$40.10M
YoY Change	-12.29%	27.49%	-17.15%
% of Gross Profit	262.13%	55.71%	64.26%
Research & Development	$113.9M	$60.00M	$78.10M
YoY Change	45.86%		37.5%
% of Gross Profit	849.01%	26.97%	125.16%
Depreciation & Amortization	$2.583M	$10.20M	$5.490M
YoY Change	-52.95%	-12.82%	9.58%
% of Gross Profit	19.25%	4.59%	8.8%
Operating Expenses	$148.7M	$183.9M	$120.4M
YoY Change	23.47%		12.0%
Operating Profit	-$135.2M	-$288.5M	-$58.00M
YoY Change	133.17%	50.37%	-42.23%
Interest Expense	$932.0K	$1.075M	-$500.0K
YoY Change	-286.4%	-55.25%	-120.83%
% of Operating Profit
Other Income/Expense, Net		-$1.078M
YoY Change		-119.41%
Pretax Income	-$134.3M	-$290.7M	-$58.50M
YoY Change	129.59%	54.02%	-40.37%
Income Tax	$112.0K	$347.0K	$200.0K
% Of Pretax Income
Net Earnings	-$134.1M	-$290.0M	-$58.60M
YoY Change	128.8%	53.22%	-40.27%
Net Earnings / Revenue	-810.48%	-123.25%	-90.15%
Basic Earnings Per Share		-$3.14
Diluted Earnings Per Share	-$1.445M	-$3.141M	-$642.5K
COMMON SHARES
Basic Shares Outstanding		92.35M
Diluted Shares Outstanding		92.35M

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$405.2M	$405.2M	$686.5M
YoY Change	-40.98%	-40.98%	28.61%
Cash & Equivalents	$171.2M	$59.80M	$678.4M
Short-Term Investments	$234.0M	$234.0M	$8.100M
Other Short-Term Assets	$5.070M	$12.45M	$1.807M
YoY Change	180.58%	22.09%	5.24%
Inventory	$31.02M	$31.02M	$16.53M
Prepaid Expenses	$7.383M		$8.353M
Receivables	$17.40M	$36.33M	$41.88M
Other Receivables	-$10.93M	-$10.93M	-$4.100M
Total Short-Term Assets	$474.1M	$474.1M	$755.1M
YoY Change	-37.22%	-37.22%	7.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$28.28M	$120.2M	$33.65M
YoY Change	-15.96%	84.0%	-21.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.825M	$171.6M	$2.728M
YoY Change	40.21%	5620.7%	-95.54%
Other Assets	$6.680M	$7.991M	$1.390M
YoY Change	380.58%	128.31%	-85.17%
Total Long-Term Assets	$299.8M	$299.8M	$71.73M
YoY Change	317.9%	318.08%	-53.69%
TOTAL ASSETS
Total Short-Term Assets	$474.1M	$474.1M	$755.1M
Total Long-Term Assets	$299.8M	$299.8M	$71.73M
Total Assets	$773.8M	$773.8M	$826.8M
YoY Change	-6.41%	-6.41%	-3.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.10M	$26.10M	$24.79M
YoY Change	5.28%	5.23%	307.18%
Accrued Expenses	$172.6M	$180.4M	$118.3M
YoY Change	45.86%	72.75%	41.18%
Deferred Revenue	$15.86M		$6.547M
YoY Change	142.2%		1236.12%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.00K	$11.00K	$12.30M
YoY Change	-99.91%	-99.91%	-0.81%
Total Short-Term Liabilities	$225.5M	$225.5M	$163.2M
YoY Change	38.18%	38.17%	58.83%
LONG-TERM LIABILITIES
Long-Term Debt	$17.62M	$17.62M	$44.10M
YoY Change	-60.05%	-60.05%	-20.54%
Other Long-Term Liabilities	$26.02M	$292.4M	$38.79M
YoY Change	-32.92%	72.61%	-40.7%
Total Long-Term Liabilities	$26.02M	$310.0M	$38.79M
YoY Change	-32.92%	45.21%	-40.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$225.5M	$225.5M	$163.2M
Total Long-Term Liabilities	$26.02M	$310.0M	$38.79M
Total Liabilities	$544.7M	$564.7M	$385.4M
YoY Change	41.34%	39.53%	19.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.264B		-$974.0M
YoY Change	29.78%		24.12%
Common Stock	$929.0K		$914.0K
YoY Change	1.64%		4.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$209.1M	$209.1M	$422.2M
YoY Change
Total Liabilities & Shareholders Equity	$773.8M	$773.8M	$826.8M
YoY Change	-6.41%	-6.41%	-3.56%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$134.1M	-$290.0M	-$58.60M
YoY Change	128.8%	53.22%	-40.27%
Depreciation, Depletion And Amortization	$2.583M	$10.20M	$5.490M
YoY Change	-52.95%	-12.82%	9.58%
Cash From Operating Activities	-$54.96M	-$82.23M	-$7.230M
YoY Change	660.17%	-200.77%	-83.95%
INVESTING ACTIVITIES
Capital Expenditures	-$1.396M	$5.186M	-$2.390M
YoY Change	-41.59%	29.84%	37.36%
Acquisitions
YoY Change
Other Investing Activities	-$49.17M	-$396.8M	$146.2M
YoY Change	-133.64%	-186.92%	-727.57%
Cash From Investing Activities	-$50.57M	-$427.0M	$143.8M
YoY Change	-135.17%	-194.36%	-674.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$12.70M
YoY Change		-66.43%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-31.00K	-563.0K	5.660M
YoY Change	-100.55%	-104.22%	-2121.43%
NET CHANGE
Cash From Operating Activities	-54.96M	-82.23M	-7.230M
Cash From Investing Activities	-50.57M	-427.0M	143.8M
Cash From Financing Activities	-31.00K	-563.0K	5.660M
Net Change In Cash	-105.6M	-507.2M	142.2M
YoY Change	-174.23%	-191.86%	-302.1%
FREE CASH FLOW
Cash From Operating Activities	-$54.96M	-$82.23M	-$7.230M
Capital Expenditures	-$1.396M	$5.186M	-$2.390M
Free Cash Flow	-$53.56M	-$87.42M	-$4.840M
YoY Change	1006.69%	-212.64%	-88.82%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M28D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M10D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M10D
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021	dei	Auditor Firm AuditorFirmId	238
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	345891000
CY2021	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2021	dei	Auditor Location AuditorLocation	San Jose, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171223000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	678393000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	233967000
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	8144000
CY2021Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	10930000
CY2020Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	4127000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17401000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41883000
CY2021Q4	us-gaap	Inventory Net InventoryNet	31015000
CY2020Q4	us-gaap	Inventory Net InventoryNet	16530000
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	0
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	889000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20453000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10160000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	474059000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	755110000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2072000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2072000
CY2021Q4	fgen	Long Term Investment Excluding Equity Method Investments LongTermInvestmentExcludingEquityMethodInvestments	167796000
CY2020Q4	fgen	Long Term Investment Excluding Equity Method Investments LongTermInvestmentExcludingEquityMethodInvestments	244000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28277000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33647000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	761000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	29606000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	3825000
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	2728000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	91112000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2043000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5919000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1390000
CY2021Q4	us-gaap	Assets Assets	773821000
CY2020Q4	us-gaap	Assets Assets	826840000
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	0
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1118000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	26097000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	24789000
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	4000
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	24000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	172588000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	118333000
CY2021Q4	fgen	Due To Related Parties Deferred Revenue Current DueToRelatedPartiesDeferredRevenueCurrent	3201000
CY2020Q4	fgen	Due To Related Parties Deferred Revenue Current DueToRelatedPartiesDeferredRevenueCurrent	2907000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15857000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6547000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	12330000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10944000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1188000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	225497000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	163187000
CY2021Q4	fgen	Accrued Product Development Costs AccruedProductDevelopmentCosts	17613000
CY2020Q4	fgen	Accrued Product Development Costs AccruedProductDevelopmentCosts	18697000
CY2021Q4	fgen	Due To Related Parties Deferred Revenue Noncurrent DueToRelatedPartiesDeferredRevenueNoncurrent	25891000
CY2020Q4	fgen	Due To Related Parties Deferred Revenue Noncurrent DueToRelatedPartiesDeferredRevenueNoncurrent	4636000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	186801000
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	138474000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	25391000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88776000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	853000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26018000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38789000
CY2021Q4	us-gaap	Liabilities Liabilities	544708000
CY2020Q4	us-gaap	Liabilities Liabilities	385391000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	125000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	125000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92881000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92881000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91441000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91441000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	929000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	914000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1476414000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1399774000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4163000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4499000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1264034000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-974011000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	209146000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	422178000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	19967000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	19271000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	229113000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	441449000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	773821000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	826840000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	176319000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	256577000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	12871000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	8869000
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	1147000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	123925000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	523839000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	368199000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-288530000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-191880000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-89314000
CY2021	us-gaap	Interest Expense InterestExpense	1075000
CY2020	us-gaap	Interest Expense InterestExpense	2402000
CY2019	us-gaap	Interest Expense InterestExpense	2876000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1078000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5553000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15548000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2153000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3151000
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	12672000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-290683000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-188729000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-76642000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	328000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1007000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-202000
CY2019	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290023000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-189291000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-76970000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.14
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.11
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.89
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92349000
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89854000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86633000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290023000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1235000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3207000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-899000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-545000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	592000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	336000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3752000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	923000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-289687000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-193043000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76047000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	528470000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-76970000
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	592000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	331000
CY2019	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	7962000
CY2020	fgen	Investment Gain Loss In Unconsolidated Variable Interest Entity InvestmentGainLossInUnconsolidatedVariableInterestEntity	-202000
CY2019	fgen	Investment Gain Loss In Unconsolidated Variable Interest Entity InvestmentGainLossInUnconsolidatedVariableInterestEntity	0
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-233000
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-933000
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	42000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	71161000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	72720000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66267000
CY2019	fgen	Warrants Exercised During Period Value WarrantsExercisedDuringPeriodValue	66000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	535406000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-189291000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-545000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3207000
CY2020	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	26366000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72720000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	441449000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290023000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-899000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1235000
CY2021	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	5494000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	71161000
CY2021	fgen	Conversion Of Subsidiarys Convertible Note Payable ConversionOfSubsidiarysConvertibleNotePayable	696000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	229113000
CY2021	us-gaap	Profit Loss ProfitLoss	-290023000
CY2020	us-gaap	Profit Loss ProfitLoss	-189291000
CY2019	us-gaap	Profit Loss ProfitLoss	-76970000
CY2021	us-gaap	Depreciation Depreciation	10170000
CY2020	us-gaap	Depreciation Depreciation	11678000
CY2019	us-gaap	Depreciation Depreciation	11147000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4639000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10369000
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10307000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-2482000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-103000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3667000
CY2021	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	-30000
CY2020	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	0
CY2019	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	88000
CY2021	fgen	Investment Gain Loss In Unconsolidated Variable Interest Entity InvestmentGainLossInUnconsolidatedVariableInterestEntity	1007000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	66267000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	60000000
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2019	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	0
CY2020	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	-258000
CY2019	us-gaap	Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment	0
CY2021	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-6803000
CY2020	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	718000
CY2019	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	42365000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-25180000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11973000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-35229000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14158000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9175000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6887000
CY2021	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	889000
CY2020	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	124321000
CY2019	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	-125210000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9854000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-123492000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	128598000
CY2021	fgen	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-4209000
CY2020	fgen	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	24000
CY2019	fgen	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	1201000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4412000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-5843000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4058000
CY2021	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	-1118000
CY2020	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	1118000
CY2019	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	0
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	805000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	17731000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3051000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	16380000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	30914000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	17707000
CY2021	fgen	Increase Decrease In Operating Lease Liabilities Current IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent	503000
CY2020	fgen	Increase Decrease In Operating Lease Liabilities Current IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent	134000
CY2019	fgen	Increase Decrease In Operating Lease Liabilities Current IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent	580000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	21549000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7169000
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3137000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	57637000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	45077000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-49941000
CY2021	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	-75000
CY2020	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	-177000
CY2019	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	194000
CY2021	fgen	Increase Decrease In Operating Lease Liabilities Non Current IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent	-4043000
CY2020	fgen	Increase Decrease In Operating Lease Liabilities Non Current IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent	-143000
CY2019	fgen	Increase Decrease In Operating Lease Liabilities Non Current IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent	692000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-12089000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-82232000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	81602000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78705000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5186000
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	25000000
CY2020	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0
CY2019	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0
CY2021	fgen	Payment Made For Investment In Unconsolidated Variable Interest Entity PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity	0
CY2020	fgen	Payment Made For Investment In Unconsolidated Variable Interest Entity PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity	3896000
CY2019	fgen	Payment Made For Investment In Unconsolidated Variable Interest Entity PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity	0
CY2021	fgen	Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity	0
CY2020	fgen	Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity	1063000
CY2019	fgen	Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity	0
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	484144000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	8192000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	411299000
CY2021	fgen	Proceeds From Sales Of Available For Sale Securities ProceedsFromSalesOfAvailableForSaleSecurities	4214000
CY2020	fgen	Proceeds From Sales Of Available For Sale Securities ProceedsFromSalesOfAvailableForSaleSecurities	10606000
CY2019	fgen	Proceeds From Sales Of Available For Sale Securities ProceedsFromSalesOfAvailableForSaleSecurities	0
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	83144000
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	456900000
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	537072000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-426972000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	452487000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	120018000
CY2021	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	5489000
CY2020	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	12620000
CY2019	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	11925000
CY2021	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	403000
CY2020	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	403000
CY2019	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	403000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7372000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11463000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12701000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4300000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4695000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-5000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-507170000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	552127000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37008000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	126266000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	89258000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	171223000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	678393000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	126266000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	94000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	135000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	174000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1009000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	884000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	460000
CY2021	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	35000000
CY2020	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	0
CY2019	us-gaap	Construction In Progress Expenditures Incurred But Not Yet Paid ConstructionInProgressExpendituresIncurredButNotYetPaid	0
CY2021	fgen	Balance In Other Receivables Related To Stock Option Exercise BalanceInOtherReceivablesRelatedToStockOptionExercise	165000
CY2020	fgen	Balance In Other Receivables Related To Stock Option Exercise BalanceInOtherReceivablesRelatedToStockOptionExercise	0
CY2019	fgen	Balance In Other Receivables Related To Stock Option Exercise BalanceInOtherReceivablesRelatedToStockOptionExercise	0
CY2021	fgen	Conversion Of Subsidiarys Convertible Note Payable To Non Controlling Interests ConversionOfSubsidiarysConvertibleNotePayableToNonControllingInterests	696000
CY2020	fgen	Conversion Of Subsidiarys Convertible Note Payable To Non Controlling Interests ConversionOfSubsidiarysConvertibleNotePayableToNonControllingInterests	0
CY2019	fgen	Conversion Of Subsidiarys Convertible Note Payable To Non Controlling Interests ConversionOfSubsidiarysConvertibleNotePayableToNonControllingInterests	0
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q2	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	1300000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation (as defined and discussed under <span style="font-style:italic;">Revenue Recognition</span> below). On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks associated with concentration of credit for cash and cash equivalents. Outside of short-term operating needs, the majority of cash on hand is invested in U.S. treasuries and money market funds. Any remaining cash is deposited with major financial institutions in the U.S., Finland, China and the Cayman Islands. At times, such deposits may be in excess of insured limits. The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc. (“Astellas”)—Related party</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca AB (“AstraZeneca”)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the accounts receivable related to roxadustat sales in China from Beijing Falikang Pharmaceutical Co., Ltd. (“Falikang”) and direct sales to distributors were not material. As of December 31, 2020, the aggregate accounts receivable related to roxadustat sales in China from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor.</p>
CY2021	fgen	Highly Liquid Investment Maturity Period HighlyLiquidInvestmentMaturityPeriod	three months or less
CY2021Q4	fgen	Restricted Time Deposits Noncurrent RestrictedTimeDepositsNoncurrent	2100000
CY2020Q4	fgen	Restricted Time Deposits Noncurrent RestrictedTimeDepositsNoncurrent	2100000
CY2021	fgen	Short Term Investments Maximum Maturity Period ShortTermInvestmentsMaximumMaturityPeriod	P12M
CY2021	fgen	Long Term Investments Minimum Maturity Period LongTermInvestmentsMinimumMaturityPeriod	P12M
CY2021	fgen	Short Term Investments Maximum Maturity Period ShortTermInvestmentsMaximumMaturityPeriod	P12M
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2021	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.
CY2021	fgen	Description Of Sales Return DescriptionOfSalesReturn	Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product’s expiration date.
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	853000
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	29800000
CY2021Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021Q4	fgen	Finance Lease Right Of Use Assets Cost FinanceLeaseRightOfUseAssetsCost	2165000
CY2020Q4	fgen	Finance Lease Right Of Use Assets Cost FinanceLeaseRightOfUseAssetsCost	50477000
CY2021Q4	fgen	Finance Lease Accumulated Amortization FinanceLeaseAccumulatedAmortization	1404000
CY2020Q4	fgen	Finance Lease Accumulated Amortization FinanceLeaseAccumulatedAmortization	20871000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	761000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	29606000
CY2021Q4	fgen	Operating Lease Right Of Use Assets Cost OperatingLeaseRightOfUseAssetsCost	100912000
CY2020Q4	fgen	Operating Lease Right Of Use Assets Cost OperatingLeaseRightOfUseAssetsCost	3934000
CY2021Q4	fgen	Operating Lease Accumulated Amortization OperatingLeaseAccumulatedAmortization	9800000
CY2020Q4	fgen	Operating Lease Accumulated Amortization OperatingLeaseAccumulatedAmortization	1891000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	91112000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2043000
CY2021Q4	fgen	Finance Lease And Operating Lease Assets FinanceLeaseAndOperatingLeaseAssets	91873000
CY2020Q4	fgen	Finance Lease And Operating Lease Assets FinanceLeaseAndOperatingLeaseAssets	31649000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	12330000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	10944000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1188000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	25391000
CY2021Q4	fgen	Finance Lease And Operating Lease Liability FinanceLeaseAndOperatingLeaseLiability	99734000
CY2020Q4	fgen	Finance Lease And Operating Lease Liability FinanceLeaseAndOperatingLeaseLiability	39762000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	88776000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4639000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10369000
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10307000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	628000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1932000
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2373000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	10722000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1151000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	891000
CY2021	us-gaap	Sublease Income SubleaseIncome	1271000
CY2020	us-gaap	Sublease Income SubleaseIncome	1201000
CY2019	us-gaap	Sublease Income SubleaseIncome	1385000
CY2021	us-gaap	Lease Cost LeaseCost	14718000
CY2020	us-gaap	Lease Cost LeaseCost	12251000
CY2019	us-gaap	Lease Cost LeaseCost	12186000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	10022000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	951000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	914000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	629000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1896000
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2196000
CY2021	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	5489000
CY2020	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	12620000
CY2019	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	11925000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	450000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	662000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	49909000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3585000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1072000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2736000
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0464
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0439
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0475
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0474
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	12000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15387000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	13469000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	16810000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	18205000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	18005000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	35877000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	15000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	117753000
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	18033000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	14000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	99720000
CY2021Q4	us-gaap	Cash Cash	111422000
CY2020Q4	us-gaap	Cash Cash	88046000
CY2021Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	1000000
CY2020Q4	us-gaap	Commercial Paper At Carrying Value CommercialPaperAtCarryingValue	0
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	58801000
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	590347000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171223000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	678393000
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	402664000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	903000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	401763000
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	8272000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	119000
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	8388000
CY2021Q4	fgen	Available For Sale Securities Bond And Mutual Funds Maturing Within One Year AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear	233967000
CY2021Q4	fgen	Available For Sale Securities Bond And Mutual Funds Maturing After One Year Through Three Years AvailableForSaleSecuritiesBondAndMutualFundsMaturingAfterOneYearThroughThreeYears	167796000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	401763000
CY2021Q4	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1363000
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2303000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	21499000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	8114000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8153000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6113000
CY2021Q4	us-gaap	Inventory Net InventoryNet	31015000
CY2020Q4	us-gaap	Inventory Net InventoryNet	16530000
CY2021Q4	us-gaap	Supplies Supplies	66909000
CY2020Q4	us-gaap	Supplies Supplies	2147000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	58909000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2147000
CY2021Q4	fgen	Supplies Net SuppliesNet	8000000
CY2020Q4	fgen	Supplies Net SuppliesNet	0
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7383000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8353000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5070000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1807000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20453000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10160000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	149285000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	144894000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	121008000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	111247000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28277000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33647000
CY2021	us-gaap	Depreciation Depreciation	10200000
CY2020	us-gaap	Depreciation Depreciation	11700000
CY2019	us-gaap	Depreciation Depreciation	11100000
CY2021Q4	fgen	Accrued Preclinical And Clinical Trial Current AccruedPreclinicalAndClinicalTrialCurrent	56283000
CY2020Q4	fgen	Accrued Preclinical And Clinical Trial Current AccruedPreclinicalAndClinicalTrialCurrent	44113000
CY2021Q4	fgen	Acquired In Process Research And Development Asset AcquiredInProcessResearchAndDevelopmentAsset	35000000
CY2020Q4	fgen	Acquired In Process Research And Development Asset AcquiredInProcessResearchAndDevelopmentAsset	0
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20909000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22800000
CY2021Q4	fgen	Accrued Contract Liabilities To Pharmaceutical Distributors Current AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent	3176000
CY2020Q4	fgen	Accrued Contract Liabilities To Pharmaceutical Distributors Current AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent	15137000
CY2021Q4	fgen	Accrued Co Promotion Expenses Current AccruedCoPromotionExpensesCurrent	25746000
CY2020Q4	fgen	Accrued Co Promotion Expenses Current AccruedCoPromotionExpensesCurrent	11537000
CY2021Q4	fgen	Accrued Profit Share Current AccruedProfitShareCurrent	7895000
CY2020Q4	fgen	Accrued Profit Share Current AccruedProfitShareCurrent	7007000
CY2021Q4	fgen	Property Taxes And Other Current PropertyTaxesAndOtherCurrent	12610000
CY2020Q4	fgen	Property Taxes And Other Current PropertyTaxesAndOtherCurrent	5970000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6074000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4869000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4895000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6900000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	172588000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	118333000
CY2021Q4	fgen	Accrued Long Term Co Promotion Liability Non Current AccruedLongTermCoPromotionLiabilityNonCurrent	15236000
CY2020Q4	fgen	Accrued Long Term Co Promotion Liability Non Current AccruedLongTermCoPromotionLiabilityNonCurrent	27424000
CY2021Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	9192000
CY2020Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	8675000
CY2021Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	1590000
CY2020Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2690000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26018000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38789000
CY2021	fgen	Number Of Product Development Obligations NumberOfProductDevelopmentObligations	11
CY2021Q4	fgen	Accrued Product Development Costs Excluding Interest AccruedProductDevelopmentCostsExcludingInterest	10700000
CY2020Q4	fgen	Accrued Product Development Costs Excluding Interest AccruedProductDevelopmentCostsExcludingInterest	11600000
CY2021Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	6900000
CY2020Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	7100000
CY2021Q4	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	49424000
CY2021Q4	us-gaap	Recorded Unconditional Purchase Obligation Due In Second Year RecordedUnconditionalPurchaseObligationDueInSecondYear	23838000
CY2021Q4	us-gaap	Recorded Unconditional Purchase Obligation RecordedUnconditionalPurchaseObligation	73262000
CY2021Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	3
CY2021Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2
CY2021	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92881000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91441000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8967000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9290000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	2304000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1893000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	10253000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7910000
CY2021Q4	fgen	Common Stock Shares Reserved CommonStockSharesReserved	119176000
CY2020Q4	fgen	Common Stock Shares Reserved CommonStockSharesReserved	114604000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9290000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.94
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3452000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	35.58
CY2021	fgen	Stock Issued During Period Shares Stock Options Exercised Full Year StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear	688000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	13.89
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1259000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	35.40
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1828000
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	34.07
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8967000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.84
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2622000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8535000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	34.76
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2460000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5241000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	32.80
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1408000
CY2021	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	538607
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	30.19
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	29.99
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	54.74
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	71161000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72720000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66267000
CY2019	fgen	Class Of Warrant Or Right Number Of Warrants Or Rights Exercised During Period ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod	4430
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10416000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7564000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9050000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-268499000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-195617000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	2538000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-22184000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	6888000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-79180000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-290683000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-188729000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76642000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	347000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	360000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	328000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	347000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	6067000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	360000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	328000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	347000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	328000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2021	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	-0.018
CY2020	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	0.024
CY2019	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	0.063
CY2021	fgen	Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets	0
CY2020	fgen	Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets	0.417
CY2019	fgen	Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets	0
CY2021	fgen	Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets	0
CY2020	fgen	Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets	-0.417
CY2019	fgen	Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets	0
CY2021	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.168
CY2020	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.232
CY2019	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.029
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.016
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.007
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.217
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.025
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	167135000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	134033000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	78832000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	62465000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	38117000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	32417000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10050000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10399000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	20415000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	8243000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5875000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	20101000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	13550000
CY2021Q4	fgen	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	84625000
CY2020Q4	fgen	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	75915000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	825000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	426167000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	342897000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	409810000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	337824000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	16357000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5073000
CY2021Q4	fgen	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	16357000
CY2020Q4	fgen	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	5073000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	16357000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5073000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	72000000.0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	124000000.0
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19900000
CY2020Q4	us-gaap	Deferred Tax Asset Intra Entity Transfer Asset Other Than Inventory DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory	78700000
CY2021	fgen	Experience Historical Ownership Changes ExperienceHistoricalOwnershipChanges	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	57700000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	700000
CY2021	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Estimated Range Not Possible SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible	The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company’s effective tax rate.
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Revenues Revenues	235309000
CY2020	us-gaap	Revenues Revenues	176319000
CY2019	us-gaap	Revenues Revenues	256577000
CY2021Q4	us-gaap	Inventory Net InventoryNet	31015000
CY2020Q4	us-gaap	Inventory Net InventoryNet	16530000
CY2021Q4	us-gaap	Inventory Net InventoryNet	31015000
CY2020Q4	us-gaap	Inventory Net InventoryNet	16530000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	28277000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33647000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	761000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	29606000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	91112000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2043000

Files In Submission

Name	View Source	Status
0001564590-22-007632-index-headers.html	Edgar Link	pending
0001564590-22-007632-index.html	Edgar Link	pending
0001564590-22-007632.txt	Edgar Link	pending
0001564590-22-007632-xbrl.zip	Edgar Link	pending
fgen-10k_20211231.htm	Edgar Link	pending
fgen-10k_20211231_htm.xml	Edgar Link	completed
fgen-20211231.xsd	Edgar Link	pending
fgen-20211231_cal.xml	Edgar Link	unprocessable
fgen-20211231_def.xml	Edgar Link	unprocessable
fgen-20211231_lab.xml	Edgar Link	unprocessable
fgen-20211231_pre.xml	Edgar Link	unprocessable
fgen-ex1036_220.htm	Edgar Link	pending
fgen-ex231_12.htm	Edgar Link	pending
fgen-ex311_11.htm	Edgar Link	pending
fgen-ex312_8.htm	Edgar Link	pending
fgen-ex321_13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g423kfl0nozv000001.jpg	Edgar Link	pending
git11m3r0fp5000001.jpg	Edgar Link	pending
git11m3r0fp5000002.jpg	Edgar Link	pending
git11m3r0fp5000003.jpg	Edgar Link	pending
git11m3r0fp5000004.jpg	Edgar Link	pending
git11m3r0fp5000005.jpg	Edgar Link	pending
git11m3r0fp5000006.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FGEN
FIBROGEN INC Stock $fgen

2021 Q4 Form 10-K Financial Statement

#000156459022007632 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FGEN FIBROGEN INC Stock $fgen

2021 Q4 Form 10-K Financial Statement

#000156459022007632 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FGEN
FIBROGEN INC Stock $fgen